# A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma

> **NCT04121260** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 21 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT04121260
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-25
- **Primary completion:** 2021-04-27
- **Final completion:** 2023-10-13
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04121260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04121260, "A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04121260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*